- Home
- APLS vs MATX Comparison
APLS vs MATX Comparison
Compare APLS & MATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLS | MATX |
|---|---|---|
| Founded | 2009 | 1882 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.4B |
| IPO Year | 2015 | 1994 |
Fundamental Metrics
Financial Performance| Metric | APLS | MATX |
|---|---|---|
| Price | $40.96 | $185.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 6 |
| Target Price | $33.59 | ★ $163.33 |
| AVG Volume (30 Days) | ★ 3.8M | 180.7K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.83% |
| EPS Growth | ★ 112.50 | N/A |
| EPS | 0.20 | ★ 1.85 |
| Revenue | $1,003,782,000.00 | ★ $3,344,500,000.00 |
| Revenue This Year | N/A | $4.65 |
| Revenue Next Year | $18.19 | $4.31 |
| P/E Ratio | $204.78 | ★ $12.34 |
| Revenue Growth | ★ 28.46 | N/A |
| 52 Week Low | $16.10 | $86.97 |
| 52 Week High | $41.00 | $180.88 |
Technical Indicators
Market Signals| Indicator | APLS | MATX |
|---|---|---|
| Relative Strength Index (RSI) | 86.68 | 69.33 |
| Support Level | $19.29 | $155.21 |
| Resistance Level | $40.98 | N/A |
| Average True Range (ATR) | 0.06 | 6.27 |
| MACD | -0.75 | 0.29 |
| Stochastic Oscillator | 82.50 | 100.00 |
Price Performance
Historical ComparisonAbout APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
About MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.